The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet? The British journal of dermatology Geller, S., Myskowski, P. L., Kim, Y. H., Moskowitz, A., Horwitz, S. 2018; 178 (2): 571

View details for DOI 10.1111/bjd.16052

View details for PubMedID 29023638